Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 47.5%

Neg 47.5% Neu 0% Pos 0%

Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.